Phio Pharmaceuticals Corp. (PHIO)
PHIO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$0.9345
+1.36% on the day
Market cap
$10.9M
Nano cap
Revenue
No annual revenue filed since the period ending 2020-12-31
Net income
No annual revenue filed since the period ending 2020-12-31
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | PHIO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001533040 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
No annual revenue filed since the period ending 2020-12-31.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B5 | 2026-04-08 |
| Latest annual report FORM 10-K | 10-K | 2026-03-05 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-08-06 |
| Latest current report FORM 8-K | 8-K | 2026-10-13 |
| Latest proxy ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS | DEFA14A | 2026-08-14 |
Source: SEC EDGAR submissions feed, 892 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BLRX | BioLineRx Ltd. | $2.17 | 0.00% | $10.8M |
| KPRX | Kiora Pharmaceuticals Inc. | $2.47 | -3.52% | $10.9M |
| LTRN | Lantern Pharma Inc. | $0.7107 | -3.57% | $10.6M |
| ENSC | Ensysce Biosciences Inc. | $0.5725 | +2.99% | $11.1M |
| BFRG | Bullfrog AI Holdings Inc. | $0.5689 | -2.55% | $10.5M |
| ACTU | Actuate Therapeutics Inc. | $0.4663 | -27.56% | $11.2M |
| TPST | Tempest Therapeutics Inc. | $0.6813 | -8.27% | $11.3M |
| BIVI | BioVie Inc. | $1.20 | -9.09% | $10.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier